Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: There are only a few and mostly small population-based epidemiological studies of primary sclerosing cholangitis (PSC).Objective: We aimed to estimate prevalence and incidence rates of PSC, and survival and malignancy risk for PSC patients in a large population-based study.Methods: We retrieved 632 PSC patients from 1990 to 2015 in the Hospital District of Helsinki and Uusimaa (HUS), comprising 29% of the Finnish population. Mortality information of the PSC patients was obtained from the national Population Registry, malignancy information from the Finnish Cancer Registry and the causes of death from the Statistics Finland. Standardized incidence ratio and standardized mortality ratio (SMR) were calculated for predefined malignancy types.Results: The crude incidence of PSC in the HUS area was 1.58/100,000 person-years, and the point prevalence in 2015 was 31.7/100,000 inhabitants. The mean time from diagnosis to death was 21.9 years. The risk for any malignancy was three-fold and the risk for colorectal carcinoma was five-fold when comparing with the general population. During the first year after diagnosis of PSC, the risk for cholangiocarcinoma is 900-fold compared to the general population and after that 150-fold. SMR for all malignant neoplasms was 5.9 (95% CI 4.2–8.1).Conclusion: We found that the incidence of PSC in the HUS area in Finland is similar or higher than previously reported from other countries. The prevalence is markedly higher than reported elsewhere, probably due to the active search of the disease, suggesting that the disease is underdiagnosed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with PSC are at increased risk of developing hepatobiliary cancer, particularly CCA, for which the risk is increased 161-398-fold compared to that in the general population.5,7,285,286”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [285]
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819 · cited 1×
“The reported mean time from the PSC diagnosis to LT or death has varied in different studies from 12 to 20 years [12,16,17].”
BackgroundBoonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717 · cited 11×
“Still, the risk for CCA was more than 200-fold increased.”
BackgroundInfluentialSoetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623 · cited 1×
“Risk for colorectal cancer (CRC) is markedly increased in IBD patients with PSC [7,8], in one study the risk of CRC in IBD-PSC-patients being more than 20-fold as compared to IBD patients without PSC [9].”
ResultWeismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.038 · Cited by 533 · cited 2×
“This may explain the difference in results of Weism€ uller’s study and our study [34].”
BackgroundResultSelf-citationACG clinical guideline: primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., & Harrison, E. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.112 · Cited by 524
K. M. BOBERG, E. A. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529850166284 · Cited by 517 · cited 1×
“The incidence is comparable to previously published studies from the Nordic countries, but prevalence is clearly higher [1,18].”
ResultPrimary sclerosing cholangitis
Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W., & Hudson, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30300-3 · Cited by 462
Tischendorf, J. J. W., Hecker, H., Krüger, M., Manns, M. P., & Meier, P. N. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00872.x · Cited by 413 · cited 2×
“The reported mean time from the PSC diagnosis to LT or death has varied in different studies from 12 to 20 years [12,16,17].”
Background
Research works printed but not linked: 1
- 10.1016/j.jhep.2009.04.009 · DOI · Paper page
Cited by
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Recent advances in clinical practice: Epidemiology of autoimmune liver diseases
Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut · doi:10.1136/gutjnl-2020-322362 · Cited by 244
Trivedi, P. J., Crothers, H., Mytton, J., Bosch, S., Iqbal, T., Ferguson, J., & Hirschfield, G. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.049 · Cited by 183
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R. E., Longarini, R., Stagno, A. M., Cristoferi, L., Ciaccio, A., Cortinovis, D. L., Invernizzi, P., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100737 · Cited by 160
“Previous studies have reported an up to 400 (cid:1) fold higher risk for CCA in PSC patients compared to the general population with the co-existence of in fl ammatory bowel disease (IBD) further increasing the risk of malignancies with a signi fi cant impact on the patient ’ s prognosis [14,15].”
Metadata
- Authors
- Barner-Rasmussen, N., Pukkala, E., Jussila, A., & Färkkilä, M.
- Affiliations
- Department of Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland;
- Tampere University (FI)
- University of Helsinki (FI)
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2020-01-02
- Volume
- 55
- Issue
- 1
- Pages
- 74-81
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2996844541
- Cited by
- 80
- References
- 34
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 9 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 4
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Scandinavian Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary sclerosing cholangitis, prevalence, incidence, survival, cancer risk, cholangiocarcinoma, colorectal cancer, standardized mortality ratio, underdiagnosis, Finland
- MeSH terms
- Adult, Bile Duct Neoplasms, Female, Finland, Humans, Male, Middle Aged, Registries, Colorectal Neoplasms, Cholangitis, Sclerosing, Incidence, Prevalence, Survival Analysis, Liver Transplantation, Age Distribution, Sex Distribution, Cholangiocarcinoma, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. https://app.cochat.ai/papers/10.1080/00365521.2019.1707277
- The paper
- Barner-Rasmussen, N., Pukkala, E., Jussila, A., & Färkkilä, M. (2020). Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scandinavian Journal of Gastroenterology. https://doi.org/10.1080/00365521.2019.1707277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.